SCHEMBL976447

SCHEMBL976447

CC(O)CC(O)CC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 1/20 0.60
GABRR1 P24046 2/20 0.50
MAPT P10636 1/20 0.50
LMNA P02545 1/20 0.50
GPR84 Q9NQS5 4/20 0.45
SMN1; SMN2 Q16637 1/20 0.42
CACNA2D1 P54289 2/20 0.41
CACNB3 P54284 1/20 0.41
CACNA1C Q13936 1/20 0.41
PGR P06401 1/20 0.41
ADRA1A P35348 1/20 0.41
HTR2B P41595 1/20 0.41
CACNA2D2 Q9NY47 1/20 0.41
TDP1 Q9NUW8 1/20 0.38
TP53 P04637 1/20 0.36
HMGCR P04035 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8292735 1.00 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL976030 1.00 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL667024 0.84 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL4748781 0.84 SLC22A6 (0.60) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL6453593 0.83 SLC22A6 (0.75) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL16600216 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL19615565 0.80 SLC22A6 (0.36) SLC22A6GABRR1MAPTLMNASMN1; SMN2
SCHEMBL14189817 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL13701365 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84
SCHEMBL28670099 0.80 SLC22A6 (0.55) SLC22A6GABRR1MAPTLMNAGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112662637-A Formate dehydrogenase mutant and preparation method and application thereof 江苏阿尔法药业有限公司 2021-04-16 CN claimed
CN-104789505-B Reduction prepares the method and strain of cis 3,5 dihydroxyhexanoate compound 苏州东和盛昌生物科技有限公司 2018-03-06 CN claimed
CN-104342410-B Ketone reductase mutant and preparation method thereof 南京朗恩生物科技有限公司 2017-04-19 CN claimed
CN-101528917-B Compositions and methods for preparing stereoisomerically pure statins and synthetic intermediates thereof CODEXIS, INC. (US) 2015-07-29 CN claimed
CN-104789505-A Method and strain for preparing cis-3,5-dihydroxyhexanoate compound by reduction and strain SUZHOU DONGHESHENGCHANG BIOTECHNOLOGY CO LTD 2015-07-22 CN claimed
CN-104342410-A Ketone reductase mutant and preparation method thereof NANJING LANG EN BIOLOG SCIENCE & TECHNOLOGY CO LTD 2015-02-11 CN claimed
EP-2066788-B1 COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR CODEXIS INC (US) 2014-07-23 EP claimed
US-8273547-B2 Engineered ketoreductases and methods for producing stereoisomerically pure statins CODEXIS, INC. (US) 2012-09-25 US claimed
EP-2240442-B1 PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN MEDICHEM KOREA CO LTD (KR) 2012-06-20 EP claimed
US-20110195465-A1 Compositions and Methods for Producing Stereoisomerically Pure Statins and Synthetic Intermediates Therefor CODEXIS, INC. (US) 2011-08-11 US claimed
US-7879585-B2 Ketoreductases of Saccharomyces cerevisiae; host cells CODEXIS, INC. (US) 2011-02-01 US claimed
EP-2066788-A2 COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR Codexis, Inc. (US) 2009-06-10 EP claimed
US-20080248539-A1 COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR CODEXIS, INC. (US) 2008-10-09 US claimed
WO-2008042876-A2 COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR CODEXIS, INC. (US) 2008-04-10 WO claimed
EP-1439162-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE KANEKA CORP (JP) 2008-03-26 EP claimed
US-6998495-B2 Method for producing optically active 3,5-dihydroxycarboxylic acid derivative KANEKA CORPORATION (JP) 2006-02-14 US claimed
US-20040254392-A1 Process for producing optically active 3,5-dihydroxycarboxylic acid derivative KANEKA CORPORATION (JP) 2004-12-16 US claimed
EP-1439162-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE KANEKA CORPORATION (JP) 2004-07-21 EP claimed
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO HERCULES CAPITAL, INC. 2025-04-24 US disclosed
US-5286883-A (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof TAKASAGO INTERNATIONAL CORPORATION (JP) 1994-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254392-A1 Process for producing optically active 3,5-dihydroxycarboxylic acid derivative HAO2, GRHPR, HDHD5 SLC22A6 4289/4885GABRR1 196/4885MAPT 4530/4885
US-20080248539-A1 COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR COASY, FAR1, HMGCR SLC22A6 2136/4885GABRR1 724/4885MAPT 3851/4885
US-20250127925-A1 DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO CSGALNACT1, CHI3L2, LNPEP SLC22A6 312/4885GABRR1 3518/4885MAPT 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.